KVUE
WAITKenvue Inc.
$19.79
+0.20%delayed
News – · Trend ▲ · inside triggers –
Expected move (1d)
▼ $19.37to$20.21 ▲
ATR ±$0.42 (+2.10%)Implied ±$1.34 (+6.80%)
Entry Reference
Price / prev close$19.79 / $19.75
Day range$19.25 – $19.81
52-wk range$14.02 – $22.35(69%)
Volume vs avg0.95×
ATR (14d)$0.42
MA 8 / 21$19.30 / $19.27
MA 50 / 200$18.44 / $17.49
Call ▲ / Put ▼ trigger$19.85 / $19.65
+1 / +2 ATR$20.21 / $20.62
-1 / -2 ATR$19.37 / $18.96
Support: 19.18 18.97 18.58
Resistance: 20.13
Near-the-money contracts
exp 2026-07-31Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 18.5 | $1.83 | 154% | 0.75 | -0.19 | 25 |
| 19 | $1.60 | 167% | 0.66 | -0.24 | 299 |
| 19.5 | $0.30 | 33% | 0.74 | -0.04 | 621 |
| 20 | $0.08 | 23% | 0.26 | -0.03 | 131 |
| 20.5 | $0.03 | 49% | 0.16 | -0.05 | 88 |
| 21 | $0.02 | 37% | 0.01 | -0.00 | 52 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 17.5 | $0.03 | 63% | -0.00 | -0.00 | 335 |
| 18 | $0.01 | 50% | -0.00 | -0.00 | 96 |
| 18.5 | $0.03 | 68% | -0.07 | -0.04 | 136 |
| 19 | $0.04 | 56% | -0.14 | -0.05 | 57 |
| 19.5 | $0.23 | 178% | -0.43 | -0.27 | 5 |
| 20 | $1.27 | 162% | -0.51 | -0.25 | 0 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook7h ago
- Is Kenvue Stock Attractive After Margin Gains and Deal Uncertainty7h ago
- Kenvue Benefits From Consumer Health Trends and Margin Expansion7h ago
- Kenvue Increases Quarterly Cash Dividend11h ago
- What Are Wall Street Analysts' Target Price for Kenvue Stock?13h ago
- Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest2d ago
- 5 Dividend Kings Continued to Pay and Raise Dividends Through Every Market Crash Since Black Monday2d ago
- Best Dividend Kings: July 20263d ago
- Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)4d ago
- Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?4d ago
- Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight4d ago
- KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback5d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.